



MASSACHUSETTS
GENERAL HOSPITAL

REPURPOSING A GENERIC TUBERCULOSIS VACCINE TO TREAT TYPE 1 DIABETES




HARVARD
MEDICAL SCHOOL

In 2008, Cures Within Reach funded **Dr. Denise Faustman** at **Massachusetts General Hospital / Harvard** to support repurposing **the generic vaccine BCG** to help patients with **Type 1 Diabetes (T1D)**. CWR first funded a screening trial, then a Phase I clinical trial. In 2018, Faustman published long-term results from this Phase I clinical trial, showing that multi-dosing BCG in long-term T1D patients can result in stable and long-term correction of blood sugars with just two doses of BCG, without further intervention. Patients with longstanding T1D before the Phase I trial had lowered blood sugar levels nearing the normal range for 5 consecutive years, without changing their care routine (no new pumps or diabetes monitoring devices). CWR funds are now supporting the Phase II clinical trial with 150 longstanding T1D patients.

Key Facts & Impact

CWR provided \$110,000 to fund the pre-clinical and Phase I/II clinical trials repurposing the BCG vaccine for Type 1 Diabetes patients, along with funds from Iacocca Foundation. The Phase I study resulted in long-term restoration of blood sugars in these patients.

CWR's early funding helped to leverage **more than \$20 million in follow-on funding** from the Iacocca Foundation for the larger FDA registration trial. Faustman has since expanded this BCG research to other diseases, including COVID-19.



Measuring CWR's Success

Clinical Trials With Early Positive Evidence

Follow-On Funding for Follow-On Clinical Trials

Clinical Results Impacting Patients Broadly

